This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Reasons to Retain Veeva Systems (VEEV) in Your Portfolio Now
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock. However, data security threats and escalating costs are a concern.
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
Roche Holding's (RHHBY) Accu-Chek SmartGuide Receives CE Mark
by Zacks Equity Research
Roche Holding (RHHBY) announces the receipt of CE Mark for its Accu-Chek SmartGuide CGM solution which is intended toward providing better diabetes management.
Philips (PHG) Gains Despite Recall of SENSE XL Torso Coils
by Zacks Equity Research
Philips (PHG) issues an urgent recall of SENSE XL Torso coils (1.5T and 3.0T) due to heating risks during MRI scans.
Why Universal Health Services (UHS) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why You Should Add DaVita (DVA) to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its kidney care raises optimism about the stock.
Masimo (MASI) Gets Non-Binding Offer for Consumer Business
by Zacks Equity Research
Masimo (MASI) gets an acquisition offer for its consumer business from an undisclosed entity. The deal is likely to close later in 2024.
GE HealthCare's (GEHC) New Solution to Aid Prostate Treatment
by Zacks Equity Research
GE HealthCare's (GEHC) MIM Software introduced the MIM Symphony HDR Prostate to provide direct tumor visualization using MRI images during live ultrasound procedures for HDR prostate treatments.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint
by Zacks Equity Research
IceCure's (ICCM) ProSense cryoablation system demonstrated a 100% complete ablation rate for breast cancer per a study published in "Cancers."
Is Universal Health Services (UHS) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Universal Health Services (UHS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Is Tenet Healthcare (THC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.
Orthofix Medical's (OFIX) Fitbone System Gets FDA Clearance
by Zacks Equity Research
Orthofix Medical (OFIX) announces the FDA clearance and first U.S. implant of the Fitbone Transport and Lengthening System, used to treat large bone defects in the femur and tibia.
Inspire Medical (INSP) Dips on FDA Recall of IPG Model 3028
by Zacks Equity Research
The recall of Inspire Medical 's (INSP) Inspire IV Implantable Pulse Generators might dampen the company's future sales.
Olink's (OLK) Acquisition by Thermo Fisher Gets UK CMA Nod
by Zacks Equity Research
Olink's (OLK) buyout by Thermo Fisher gets CMA's approval, signaling regulatory confidence in the merger's compliance with competition laws.
Stryker (SYK) Gains 11.6% YTD: What's Driving the Stock?
by Zacks Equity Research
Styker's (SYK) flagship Mako Total Knee Platform and a diversified product portfolio raise optimism about the stock.
Baxter (BAX) Recovers After Life2000 Ventilation Systems Recall
by Zacks Equity Research
Baxter (BAX) recalls Life2000 ventilators due to damaged battery charger dongles, posing a risk of device failure
Smith & Nephew's (SNN) 5% Stake Acquired by Cevian Capital
by Zacks Equity Research
Smith & Nephew (SNN) eyes future growth as Cevian Capital purchases a 5% stake in the company.
Microbot Medical (MBOT) Inks Agreement to Begin LIBERTY Trial
by Zacks Equity Research
Microbot Medical's (MBOT) LIBERTY Endovascular Robotic System trial expands to Baptist Hospital of Miami, promising advancements in clinical outcomes and endovascular procedures.
Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data
by Zacks Equity Research
Lucid Diagnostic's (LUCD) ESOGUARD BE-1 study data shows high sensitivity and negative predictive value for the EsoGuard test, enhancing early detection of esophageal precancer in a screening population.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
DaVita's (DVA) strength in its kidney care segment raises optimism about the stock.
KORU Medical's (KRMD) FreedomEdge Gets Regulatory Nod in Japan
by Zacks Equity Research
KORU Medical (KRMD) announces the receipt of regulatory clearance for its FreedomEdge System in Japan.
IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod
by Zacks Equity Research
IceCure Medical's (ICCM) XSense Cryoablation System receives FDA approval, marking a pivotal step in minimally-invasive tumor treatment across multiple medical fields